| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | ceritinib (Zykadia®) |
| Formulation | 150 mg capsule |
| Reference number | 2024 |
| Indication | Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/05/2015 |
| NICE guidance | |